Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

TScan Therapeutics (TCRX) Free Cash Flow (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Free Cash Flow for 6 consecutive years, with -$32.2 million as the latest value for Q4 2025.

  • Quarterly Free Cash Flow fell 4.6% to -$32.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$139.7 million through Dec 2025, down 21.87% year-over-year, with the annual reading at -$139.7 million for FY2025, 21.87% down from the prior year.
  • Free Cash Flow for Q4 2025 was -$32.2 million at TScan Therapeutics, up from -$33.9 million in the prior quarter.
  • The five-year high for Free Cash Flow was $5.4 million in Q3 2023, with the low at -$37.9 million in Q1 2025.
  • Average Free Cash Flow over 5 years is -$21.6 million, with a median of -$21.3 million recorded in 2023.
  • The sharpest move saw Free Cash Flow soared 131.26% in 2023, then tumbled 594.4% in 2024.
  • Over 5 years, Free Cash Flow stood at -$13.8 million in 2021, then fell by 15.25% to -$15.9 million in 2022, then tumbled by 34.68% to -$21.4 million in 2023, then crashed by 43.79% to -$30.8 million in 2024, then fell by 4.6% to -$32.2 million in 2025.
  • According to Business Quant data, Free Cash Flow over the past three periods came in at -$32.2 million, -$33.9 million, and -$35.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.